Clinical Trial: A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253142) titled 'A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer' on Nov. 19.

Brief Summary: The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.

Study Start Date: Jan. 14, 2026

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer Small Cell Lung Cancer

Intervention: DRUG: HLX43 dose 1

HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA t...